Table 1.
Patient characteristics
| Parameter | Statistics | Anti-Her2 group | Exclusively ET Group |
Study population | p value |
|---|---|---|---|---|---|
| Age | Median | 53 | 65.5 | 59 | *1.63E−02 |
| Range | 36–72 | 52–78 | 31–89 | ||
| Bone metastasis | |||||
| No | N (%) | 18 (60) | 6 (75) | 89 (50) | 1.41E−01 |
| Yes | N (%) | 12 (40) | 2 (25) | 89 (50) | |
| Liver metastasis | |||||
| No | N (%) | 21 (70) | 7 (87.5) | 119 (66.9) | 3.89E−01 |
| Yes | N (%) | 9 (30) | 1 (12.5) | 59 (33.1) | |
| Lung metastasis | |||||
| No | N (%) | 19 (63.3) | 5 (62.5) | 116 (65.2) | 9.57E−01 |
| Yes | N (%) | 11 (36.7) | 3 (37.5) | 62 (34.8) | |
| T | |||||
| T1 | N (%) | 10 (33.3) | 2 (25) | 54 (30.3) | 8.83E−01 |
| T2 | N (%) | 13 (43.3) | 3 (37.5) | 82 (46.1) | |
| T3 | N (%) | 3 (10) | 0 (0) | 16 (9) | |
| T4 | N (%) | 3 (10) | 2 (25) | 19 (10.7) | |
| Tis | N (%) | 0 (0) | 0 (0) | 1 (0.6) | |
| NA | N (%) | 1 (3.3) | 1 (12.5) | 6 (3.4) | |
| Grading | |||||
| G1 | N (%) | 1 (3.3) | 1 (12.5) | 7 (3.9) | 1.84E−01 |
| G2 | N (%) | 10 (33.3) | 6 (75) | 82 (46.1) | |
| G3 | N (%) | 13 (43.3) | 0 (0) | 66 (37.1) | |
| NA | N (%) | 6 (20) | 1 (12.5) | 23 (12.9) | |
| Estrogen receptor (ER) | |||||
| Positive | N (%) | 15 (50) | 8 (100) | 134 (75.3) | *8.37E−04 |
| Negative | N (%) | 15 (50) | 0 (0) | 39 (21.9) | |
| NA | N (%) | 0 (0) | 0 (0) | 5 (2.8) | |
| Progesterone receptor (PR) | |||||
| Positive | N (%) | 13 (43.3) | 6 (75) | 116 (65.2) | *1.08E−02 |
| Negative | N (%) | 17 (56.7) | 2 (25) | 54 (30.3) | |
| NA | N (%) | 0 (0) | 0 (0) | 8 (4.5) | |
| Her2 | |||||
| Negative | N (%) | 8 (26.7) | 8 (100) | 133 (74.7) | *2.63E−16 |
| Positive | N (%) | 19 (63.3) | 0 (0) | 24 (13.5) | |
| NA | N (%) | 3 (10) | 0 (0) | 21 (11.8) | |
| CTC | |||||
| Negative | N (%) | 25 (83.3) | 5 (62.5) | 110 (61.8) | *1.40E−05 |
| Positive | N (%) | 5 (16.7) | 1 (12.5) | 64 (36) | |
| NA | N (%) | 0 (0) | 2 (25) | 4 (2.2) | |
| Surgery | |||||
| No | N (%) | 7 (23.3) | 3 (37.5) | 28 (15.7) | 8.05E−02 |
| Yes | N (%) | 23 (76.7) | 5 (62.5) | 150 (84.3) | |
| Radiation | |||||
| No | N (%) | 16 (53.3) | 6 (75) | 67 (37.6) | *7.80E−03 |
| Yes | N (%) | 14 (46.7) | 2 (25) | 111 (62.4) | |
Anti-Her2 Group are the patients who received anti-Her2 therapy before being included in the study: exclusively ET group are the patients who did not receive any other therapy except for endocrine therapy